🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

Recruitingn/aAges any - anyMaleNovartis Pharmaceuticals
NCT07484269 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The primary objective of the study is to describe real-world drug utilisation of lutetium (177Lu) vipivotide tetraxetan among patients with metastatic prostate cancer

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: Age ≥ 18 years at index date * Diagnosis of mPC * PSMA positive * Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date Exclusion criterion: • Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)
💊

What it tests

  • Not listed
📍

Where

1 site
Novartis Investigative SIte
Basel, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy